Last reviewed · How we verify
Polio Sabin™ vaccine
Polio Sabin™ vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of poliomyelitis.
The Polio Sabin vaccine works by introducing a weakened form of the poliovirus to stimulate an immune response.
The Polio Sabin vaccine works by introducing a weakened form of the poliovirus to stimulate an immune response. Used for Prevention of poliomyelitis.
At a glance
| Generic name | Polio Sabin™ vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This immune response helps the body develop antibodies to fight the poliovirus, providing protection against polio infection. The weakened virus is unable to cause disease but still triggers an immune response, which is essential for long-term immunity.
Approved indications
- Prevention of poliomyelitis
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028) (PHASE1)
- Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults (PHASE1)
- A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children (PHASE4)
- A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania (PHASE4)
- Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™ (PHASE3)
- Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049) (PHASE3)
- Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants (PHASE2)
- Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polio Sabin™ vaccine CI brief — competitive landscape report
- Polio Sabin™ vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Polio Sabin™ vaccine
What is Polio Sabin™ vaccine?
How does Polio Sabin™ vaccine work?
What is Polio Sabin™ vaccine used for?
Who makes Polio Sabin™ vaccine?
What development phase is Polio Sabin™ vaccine in?
What are the side effects of Polio Sabin™ vaccine?
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of poliomyelitis
- Compare: Polio Sabin™ vaccine vs similar drugs
- Pricing: Polio Sabin™ vaccine cost, discount & access